GSEA showed that there were significant differences between the high-risk and low-risk groups in the ERBB pathway and small cell lung cancer pathway, which overlapped with our results of immune function analysis and further demonstrated that our prognostic model was inseparable from cancer and immunity. The gene discussed is EGFR; the disease is cancer.